We are live on ! Find out more

NeoGenomics

NEO

Market cap $2.37B

18.47 USD

+0.69

3.88%

At close Updated Oct 2, 4:00 PM EDT

Pre-market

After hours

18.47

0.00

0%

1 day

3.88%

5 days

-2.89%

1 month

6.15%

3 months

21.83%

6 months

130.88%

Year to date

57.06%

1 year

105.68%

5 years

-57.27%

10 years

128.59%

About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Employees: 2,500

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

Neo Performance Materials Q2 Earnings Call Highlights

Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.

Neo Performance Materials Q2 Earnings Call Highlights

Zacks Investment Research

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics Reports Second Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice (“DOJ”) on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021. As the DOJ acknowledged in the settlement agreement, the Company cooperated with the government's investigation into the matter.

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

See News Rankings

Price charts implemented using Lightweight Charts™